Lilly's Triple-G Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Type 2 Diabetes Trial

on

Eli Lilly's retatrutide, a GIP, GLP-1, and glucagon triple agonist, met primary endpoints in the TRANSCEND-T2D-1 phase 3 trial, reducing A1C by 1.7% to 1.9% at 40 weeks across 4-mg, 9-mg, and 12-mg doses12

Participants on the 12-mg dose achieved 16.8% average body weight loss (36.6 pounds) using the efficacy estimand, with no weight loss plateau observed by week 4012

The trial enrolled 537 adults with type 2 diabetes; discontinuation due to adverse events at 12-mg was 5.1%, with common side effects including nausea (26.5%), diarrhea (22.8%), and vomiting (17.6%)12

Results are competitive with approved GLP-1 drugs like Ozempic and Mounjaro, showing superior A1C and weight loss reductions compared to placebo1

This data builds on prior phase 3 results, such as 28.7% weight loss in obesity with knee osteoarthritis patients1

Sources:

1. https://www.fiercebiotech.com/biotech/eli-lilly-retatrutide-type-2-diabetes-weight-loss-ph-3-data

2. https://www.biospace.com/press-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes